Blood levels of a nerve-damage marker fell by 13 per cent after 12 weeks of time-restricted eating in 20 people with early-stage Huntington's disease. The finding comes from the first clinical trial to test the approach in Huntington's disease.

The pilot study was led by Oregon Health & Science University (OHSU) and published in Nature Metabolism on 17 September 2026. Researchers stressed that the findings do not prove intermittent fasting slows the disease.

The small, open-label study had no comparison group, making larger randomised trials necessary. Huntington's disease affects movement, cognition and mood and has no cure or established treatment that stops its progression.

Testing Time-Restricted Eating

Participants selected a daily eating window that suited their routines, typically lasting six to eight hours. They were encouraged to maintain their usual calorie intake rather than deliberately restrict food.

That meant avoiding calorie-containing food and drink for the remaining 16 to 18 hours. Participants followed the schedule more than five days a week on average and most adapted within one to two weeks.

Weight loss is a concern in Huntington's disease, making the results notable. Participants maintained body weight and lean muscle mass while reporting few side effects during the 12-week intervention.

Study participant Anna White of Portland said the fasting schedule became easier than she expected. She said she could eat the foods she liked while monitoring her weight during the study.

Read more

Signals of Biological Change

Neurofilament light is a blood biomarker associated with nerve-cell damage and usually rises as Huntington's disease progresses. In this study, levels fell by an average of 13 per cent after 12 weeks.

Participants also improved by an average of 0.5 points on the composite Unified Huntington's Disease Rating Scale, or cUHDRS. The score typically declines by about one point a year in early-stage disease.

Researchers also found favourable changes in several measures of mitochondrial activity in blood cells. However, those findings do not show that mitochondria inside brain cells became more efficient.

Why Caution Still Matters

Each child of a parent with Huntington's disease has a 50 per cent chance of inheriting the disease-causing gene. The Huntington's Disease Society of America estimates that about 41,000 Americans have symptoms and more than 200,000 are at risk.

The study grew from earlier animal research suggesting fasting can influence cellular pathways linked to brain-cell protection. Researchers proposed that fasting may act as a mild stressor that changes how cells produce and manage energy.

However, the study cannot establish whether time-restricted eating changed the underlying disease. Changes in biomarkers or clinical scores could reflect natural variation or other factors rather than the eating schedule itself.

The OHSU team is seeking funding for a larger randomised clinical trial comparing time-restricted eating with standard dietary habits. Such a study would help determine whether the early signals are sustained and clinically meaningful.

Adult-onset Huntington's disease most often begins between 30 and 50 years of age. Its progression varies between individuals, but the condition gradually causes increasing motor, cognitive and psychiatric difficulties.

The findings are therefore best viewed as an early signal that meal timing may be worth investigating in Huntington's disease. The researchers describe the results as supporting further investigation, not evidence of a new therapy.

For now, the findings offer a reason for further research rather than a proven treatment. People with Huntington's disease should not assume intermittent fasting can slow progression, particularly because maintaining body weight is important.

Read more